Claims for Patent: 5,972,704

Summary for Patent: 5,972,704

Title:	HIV nef targeted ribozymes
Abstract:	An enzymatic nucleic acid molecule which cleaves an immunodeficiency virus RNA in a gene required for viral replication, e.g., the nef or tat gene regions.
Inventor(s):	Draper; Kenneth G. (Boulder, CO), Chowrira; Bharat (Boulder, CO), McSwiggen; James (Boulder, CO), Stinchcomb; Dan T. (Boulder, CO), Thompson; James D. (Boulder, CO)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	08/910,408
Patent Claims:	1. An enzymatic nucleic acid molecule which specifically cleaves RNA encoded by the nef gene of human immunodeficiency virus. 2. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a hammerhead motif. 3. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a hairpin motif. 4. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a group I intron, group II intron, hepatitis delta virus ribozyme or RNase P M1 RNA motif. 5. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule comprises a substrate binding site having between 12 and 100 nucleotides complementary to said nef RNA. 6. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule comprises a substrate binding site having between 14 and 24 nucleotides complementary to said nef RNA. 7. An expression vector comprising nucleic acid sequence encoding one or more enzymatic nucleic acid molecule of claim 1 in a manner which allows expression of said enzymatic nucleic acid molecules. 8. The expression vector of claim 7, wherein said expression vector is a viral vector. 9. The expression vector of claim 8, wherein said viral vector is a retrovirus vector. 10. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is chemically synthesized. 11. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic molecule is in a purified form. 12. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic RNA molecule is active in the presence of divalent metal ions. 13. The enzymatic nucleic acid molecule of claim 12, wherein said divalent metal ion is magnesium. 14. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic molecule comprises a sugar modification. 15. The expression vector of claim 7, wherein said nucleic acid sequence encoding said enzymatic RNA molecule is under the control of a mammalian transcription promoter. 16. The expression vector of claim 15, wherein said mammalian transcription promoter is from a cytomegalovirus. 17. A method of cleaving RNA encoded by the nef gene comprising the step of contacting said RNA with the enzymatic nucleic acid molecule of claim 1 under conditions suitable for the cleavage of said RNA. 18. A mammalian cell including the enzymatic nucleic acid molecule of claim 1, wherein the mammalian cell is not part of a mammal. 19. The mammalian cell of claim 18, wherein said mammalian cell is a human cell. 20. A mammalian cell including the expression vector of claim 7. 21. The mammalian cell of claim 20, wherein said mammalian cell is a human cell. 22. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule comprises a poly A tail.

Details for Patent 5,972,704

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2012-05-14
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2012-05-14
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2012-05-14